50.37 USD
↘ 1.30 (2.52%)AT CLOSE (11:59 AM EDT)
AnaptysBio, Inc. Common Stock
ANABNASDAQ • USD
50.39
↗ 0.03 (0.05%)
POST MARKET (AS OF 07:14 PM EDT)
Post Market
AS OF 07:14 PM EDT
50.39
↗ 0.03 (0.05%)
Market: CLOSED
Open?$50.58
High?$52.28
Low?$50.36
Prev. Close?$51.67
Volume?612.0K
Avg. Volume?655.2K
VWAP?$51.23
Rel. Volume?0.93x
Bid / Ask
Bid?$20.80 × 100
Ask?$70.00 × 1.3K
Spread?$49.20
Midpoint?$45.40
Valuation & Ratios
Market Cap?1.5B
Shares Out?29.1M
Float?17.1M
Float %?61.6%
P/E Ratio?N/A
P/B Ratio?114.99
EPS?-$0.92
Dividend?0.00%
Ex-Dividend?N/A
AnaptysBio, Inc. Common Stock (ANAB) trades at $50.37 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Employees
104
Market Cap
1.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2017-01-26
Address
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO, CA 92121
Phone: 858-362-6295
SAN DIEGO, CA 92121
Phone: 858-362-6295
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?18
Momentum?50
Short Sent.?31
Piotroski F-Score?1/9Weak
Altman Z-Score?1.38Distress
Confidence?65%Moderate
Short InterestSqueeze Risk
Short % of Float?28.13%Squeeze Risk
Short Interest?4.8M
Days to Cover?7.3
Free Float17.1M
Avg Daily Volume661.0K
Settlement Date2026-05-15
Financial Health
Current Ratio?7.58Strong
Quick Ratio?7.58Strong
Cash Ratio?5.96Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score47/100
P/E?N/A▾
P/B?114.99HIGH▾
Peers100
S&P3
P/S?6.31FAIR▾
Peers100
S&P20
P/FCF?332.5PRICEY▾
Peers100
S&P3
EV/EBITDA?29.5HIGH▾
Peers100
S&P10
EV/Sales?5.24FAIR▾
Peers100
S&P34
Returns & Efficiency
ROE?-210.1%WEAK▾
S&P3
ROA?-8.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$4.4M
Enterprise Value?$1.2B
Fundamentals ratios updated end of day